BioGeneration Ventures

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing. Currently pharmaceutical companies spend a billion dollar figure on the development of a new drug entity, with a 90% chance of it failing to reach the market. The most common reason for failure during this developmental stage is drug induced cardiac toxicity. To solve this issue we develop 3D cardiac tissues, resembling the working human heart, for advanced drug discovery and toxicity screening using a multidisciplinary human stem cell-based approach.

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.

Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.

Azafaros B.V. manufactures therapeutic agents for the treatment of rare metabolic disorders. Its products can be used to cure lysosomal storage disorders (LSDs) a broad class of severe and sometimes life-threatening inherited diseases. The company is based in Leiden, the Netherlands.

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Azafaros B.V. manufactures therapeutic agents for the treatment of rare metabolic disorders. Its products can be used to cure lysosomal storage disorders (LSDs) a broad class of severe and sometimes life-threatening inherited diseases. The company is based in Leiden, the Netherlands.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.

Escalier Biosciences B.V. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2016 and is based in Nijmegen, the Netherlands.

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular and layered structures. Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.

Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec. CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases.

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.

Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec. CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases.

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.

Synaffix BV is a clinical-stage biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability. The company features technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody and a patent portfolio provides patent protection of resulting Products through at least 2035. The company's technology employs an enzymatic modification of naturally occurring glycan anchor points found on all antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry, allowing clinicians to design complex biological drugs without the need for prior genetic modifications.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.

Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers. Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

FlexGen is an innovative biotech company based in Leiden, the Netherlands. FlexGen is a spin-off from Leiden University Medical Centre (LUMC) and Dutch Space (part of EADS) and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. FlexGen commercializes the FlexArrayer, a bench-top instrument for custom microarray and oligopool synthesis. FlexGen works at the forefront of innovative microarray and oligopool applications.

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.